Muutke küpsiste eelistusi

E-raamat: Building a National Capability to Monitor and Assess Medical Countermeasure Use During a Public Health Emergency: Going Beyond the Last Mile: Proceedings of a Workshop

  • Formaat: 120 pages
  • Ilmumisaeg: 20-Dec-2017
  • Kirjastus: National Academies Press
  • Keel: eng
  • ISBN-13: 9780309466431
Teised raamatud teemal:
  • Formaat - PDF+DRM
  • Hind: 4,08 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
  • Formaat: 120 pages
  • Ilmumisaeg: 20-Dec-2017
  • Kirjastus: National Academies Press
  • Keel: eng
  • ISBN-13: 9780309466431
Teised raamatud teemal:

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

During public health emergencies (PHEs) involving chemical, biological, radiological, or nuclear threats or emerging infectious diseases, medical countermeasures (MCMs) (e.g., drugs, vaccines, devices) may need to be dispensed or administered to affected populations to help mitigate the human health impact of the threat. The optimal MCMs determined for use during an emergency might be U.S. Food and Drug Administration (FDA) approved but used in unapproved ways (e.g., in a new age group or against a new agent); FDA approved using animal models because human efficacy testing is not ethical or feasible; or not yet FDA approved for any indication.





As part of the United States' scientific and research preparedness enterprise, there is an imperative to go "beyond the last mile" of MCM dispensing and administration to build and maintain a national capability to monitor and assess the use of MCMs (e.g., safety, compliance, clinical benefit) after they have been dispensed during PHEs. To further the discussion on this need, the Board on Health Sciences Policy of the National Academies of Sciences, Engineering, and Medicine hosted a 2-day public workshop, Building a National Capability to Monitor and Assess Medical Countermeasure Use in Response to Public Health Emergencies. The workshop, sponsored by FDA, was held on June 6-7, 2017, in Washington, DC. Workshop participants discussed the roles and efforts of the federal government and of relevant stakeholders with an interest in building and maintaining a national PHE MCM active monitoring and assessment capability. This publication summarizes the presentations and discussions from the workshop.

Table of Contents



Front Matter 1 Introduction and Overview 2 Setting the Stage: Defining Terminologies and Sharing Stakeholder Perspectives 3 Data Needs, Data Sources, and Collection Methodologies for Stakeholder Decision Making 4 Considerations for Conducting Rapid Clinical Research on MCMs During a PHE 5 Inspiring Collective Action: Perspectives from Federal Stakeholders and Reflections from Individual Workshop Participants Appendix A: References Appendix B: Workshop Agenda Appendix C: Biographical Sketches of Workshop Speakers and Moderators
Acronyms and Abbreviations xiii
1 Introduction and Overview
1(16)
Workshop Background and Objectives
3(1)
Organization of This Proceedings of a Workshop
3(2)
Viewpoint from the U.S. Food and Drug Administration on MCM Monitoring and Assessment During a PHE
5(4)
Overview of Cross-Cutting Topics Highlighted During Presentations and Discussions
9(8)
2 Setting the Stage: Defining Terminologies and Sharing Stakeholder Perspectives
17(14)
Defining Terminologies Used Throughout the Workshop
18(5)
Stakeholder Perspectives
23(8)
3 Data Needs, Data Sources, and Collection Methodologies for Stakeholder Decision Making
31(20)
Defining and Answering Questions to Inform Data Needs for MCM Distribution and Monitoring
31(4)
Considerations and Approaches to Data Collection
35(3)
Integrating Data from Different Sources
38(2)
Existing Data Sources and Datasets
40(5)
Disseminating Data and Information
45(1)
Unique Challenges and Opportunities for Data Collection
46(5)
4 Considerations for Conducting Rapid Clinical Research on MCMs During A Phe
51(14)
Potential Elements of Clinical Research on MCM Use
52(3)
Data and Information Sharing
55(4)
Governance
59(6)
5 Inspiring Collective Action: Perspectives From Federal Stakeholders and Reflections from Individual Workshop Participants
65(14)
Federal Stakeholder Perspectives on Moving Forward
66(6)
Prioritizing Issues for Action: Reflections from Individual Workshop Participants
72(5)
Closing Remarks
77(2)
APPENDIXES
A References
79(2)
B Workshop Agenda
81(8)
C Biographical Sketches of Workshop Speakers and Moderators
89